James Nathanielsz

CEO and Executive Chairman

James Nathanielsz has served as a director and Chief Executive Officer of our company since October 2007. From July 2006 until October 2007, Mr. Nathanielsz served as the New Products Manager of Biota Holdings Limited, an anti-infective drug development company in Australia. Mr. Nathanielsz was selected as a director because he is the Co-Founder of Propanc and for his experience in R&D and manufacturing and distribution.

Mr. Nathanielsz holds a B.App.Sci in Biochemistry/Applied Chemistry and an M.E.I. from Swinburne University of Technology in Melbourne, Australia.

Prof. Dr. Klaus Kutz

Chief Medical Officer

Prof. Dr. Klaus Kutz is a German physician and consultant with over 25 years of independent experience in Clinical Pharmacology and Drug Safety, following 12 years in senior international roles at Sandoz and Sanofi. As founder of AccelPharm, he supports small and mid-sized pharmaceutical companies and CROs in early clinical development, regulatory submissions (INDs, NDAs), and safety oversight. His therapeutic expertise spans oncology, cardiovascular disease, gastroenterology, metabolism, neurology, dermatology, and pharmacotherapy in the elderly. A Professor of Medicine at the University of Bonn, he is board-certified in Internal Medicine, Gastroenterology, and Clinical Pharmacology, and fluent in German, English, and French.

Dr. Ralf Brandt

Research & Development Director

Dr. Ralf Brandt. is a distinguished pharmaceutical and oncology research executive with over 30 years of experience in drug discovery, oncology, angiogenesis, and preclinical development. He has held senior leadership roles including CEO and Founder of vivoPharm Pty Ltd and vivoPharm Global Pty Ltd,  President Discovery at CGIX and VYANT Bio Inc. , and executive positions at Novartis and Bionomics Ltd. Dr. Brandt has advanced more than 50 compounds to clinical studies by generating and presenting non-clinical data to client and/or regulatory bodies, holds five international patents, and authored 27 peer-reviewed publications and several book chapters. He is an expert in in vivo and in vitro pharmacology, cell biology, animal model development, GLP compliance, and translational research, and serves on several scientific advisory boards globally. He earned his PhD in Biochemistry from the Max Delbrück Center for Molecular Medicine, Berlin, and has received multiple awards including the prestigious Fogarty Fellowship (NIH, USA).

Jeannine Zimmerman

Chief Financial Officer

Ms. Zimmerman graduated from St. Joseph’s College with a Bachelor of Science degree in accounting. She began her business career at SEC Solutions Group, LLP, which specialized in providing public companies with assistance with their SEC filing requirements where she assisted on all phases of the public filings, including audit and review preparation, internal control and SOX 404 testing, financial statement analysis and review, and audit documentation maintenance. Following that, Ms. Zimmerman joined two different public and not-for-profit accounting firms, where she worked with a variety of clients including real estate, school districts, manufacturing, distribution, logistics, waste management, and communications. She has vast experience with small and large organizations, with an extensive knowledge of the Accounting Standards Codification.